Loading patent…
AssigneeSagittarius Life Science Corp.
InventorsYi Ming Tsai, Kou Mark Hwang, Suying Liu
Estimating the term…
The present invention provides Chinese herbal compositions, ST 188L and method for prevention and treatment of cancers and infectious diseases. The Chinese herbal compositions comprise a formulation prepared ratably from a group of herbal plants consisting essentially of Ecchinops grijissii, Cirsium segetum Bge, Solanum indicum Linn, Lonicerae flos, and Zizyphi fructus. ST188L appeared to be activated in vivo to stimulate the activity of NK cells and LAK cells as shown by the increases in cytolytic activity of peripheral blood mononuclear cells isolated from volunteers after intake of ST 188L toward target cells, such as K562, Daudi, HepG2 and HBV transfected HepG2-2215 in a dose dependent manner. ST 188L has been proven to be effective on eradicating malignancy in a cancer patient by enhancing said patients' endogenous immune system to keep said patient cancer free for more than ten years.
A pharmaceutical composition for treating nasopharyngeal carcinomas comprising effective amounts of Echlinops grijissii, Cirsium segetum Bge, Solanum indicum Linn, Lonicerae flos, and Zizyphi fructus in a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition for enhancing endogenous immune system of a recipient by activation of said recipient's natural killer cells and lymphokine activated killer cells comprising effective amounts of Echinops grijissii, Cirsium segetum Bge, Solanum indicum Linn, Lonicerae flos, and Zizyphi fructus in a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition exhibiting anti-viral activity for treating human hepatitis B virus comprising effective amounts of Echinops grijissii, Cirsium segetum Bge, Solanum indicum Linn, Lonicerae flos, and Zizyphi fructus in a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.